Ingersoll Rand Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ingersoll Rand Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.38B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $1.94B | Feb 16, 2018 |
| FY2017 | Dec 31, 2015 | $2.13B | Feb 16, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.65B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.24B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $6.88B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $5.92B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $5.15B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $3.97B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $2.02B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.69B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.38B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.94B | Feb 27, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.34B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.17B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.88B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $2.33B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.99B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.40B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $778.30M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.01B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $897.90M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $716.70M | Feb 27, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $581.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $838.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $778.70M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $604.70M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $562.50M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($33.30M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $159.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $269.40M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $18.40M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($36.60M) | Feb 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.30B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.16B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $817.30M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $565.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $59.60M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $194.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $443.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $109.10M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $103.50M | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $116.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $108.20M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $91.30M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $74.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $58.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $22.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $24.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $26.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $22.00M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.34B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.27B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.10B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.03B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $789.30M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $409.60M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $434.60M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $446.20M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $415.10M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.38B | Feb 17, 2026 |
| FY2020 | Dec 31, 2020 | $914.30M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $343.30M | Feb 26, 2021 |
| FY2020 | Dec 31, 2018 | $444.50M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $200.50M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $165.60M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $172.10M | Feb 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.30B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $18.01B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $15.56B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $14.77B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $15.15B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $16.06B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $4.63B | Feb 26, 2021 |
| FY2020 | Dec 31, 2018 | $4.49B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $4.62B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $4.32B | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.14B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.76B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.72B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $5.51B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $6.08B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $6.87B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.76B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.81B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.14B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $4.04B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.09B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.18B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $9.78B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $9.20B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $9.00B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $9.12B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.87B | Feb 26, 2021 |
| FY2017 | Dec 31, 2017 | $1.48B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $265.90M | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.48B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $8.15B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $6.61B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $6.06B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $5.98B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $5.58B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $1.09B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.29B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.23B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.15B | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.05B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.50B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.70B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $950.90M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $378.60M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($175.70M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($141.40M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($308.70M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($577.80M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($596.20M) | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.60B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.61B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.11B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.75B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $505.50M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $221.20M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $393.30M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $255.80M | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 590.60M | Feb 25, 2022 |
| FY2021 | Dec 31, 2021 | $2.78B | Feb 25, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 391.12M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 402.88M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 403.35M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 405.12M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 407.79M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 418.63M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 205.07M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 198.17M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 196.22M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 148.65M | Feb 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $32.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $32.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $32.40M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $8.20M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $0 | Feb 25, 2022 |